Advisory Board April 19, 2024
Zepbound, the weight-loss drug developed by Eli Lilly, helped improve sleep apnea symptoms in patients classified as overweight or obese, according to a new study announced by the drugmaker on Wednesday.
What the future of weight management drugs could hold
Study details
For the study, researchers performed two trials with overweight or obese patients who had moderate-to-severe obstructive sleep apnea, with moderate being defined as a person who stopped breathing at least 15 times an hour during sleep.
In one of the trials, which involved around 200 people with obesity who couldn’t or weren’t willing to use a CPAP machine, half were assigned Zepbound as a weekly injection, while the other half received a placebo.
The group that received Zepbound...
Today's Sponsors
Today's Sponsor